Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 7/20 | 0.67 |
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | MGLL | Q99685 | 2/20 | 0.56 |
| ▸ | G6PD | P11413 | 1/20 | 0.53 |
| ▸ | PMM2 | O15305 | 1/20 | 0.53 |
| ▸ | MPI | P34949 | 1/20 | 0.53 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20987705 | 0.87 | CASP3 (0.63) | CASP3FAAHMGLLG6PDPMM2 | |
| SCHEMBL29678965 | 0.80 | CASP3 (1.00) | CASP3FAAHMGLLG6PD | |
| SCHEMBL3143600 | 0.80 | CASP3 (1.00) | CASP3FAAHMGLLG6PD | |
| SCHEMBL11278746 | 0.80 | CASP3 (0.74) | CASP3FAAHMGLLG6PD | |
| SCHEMBL17948304 | 0.80 | CASP3 (0.72) | CASP3FAAHMGLL | |
| SCHEMBL20937506 | 0.78 | CASP3 (0.59) | CASP3G6PD | |
| SCHEMBL358740 | 0.77 | FAAH (0.77) | CASP3FAAHMGLLG6PD | |
| SCHEMBL24836231 | 0.77 | FAAH (0.81) | CASP3FAAHMGLLG6PD | |
| SCHEMBL2963555 | 0.77 | CASP3 (0.68) | CASP3FAAHMGLLG6PD | |
| SCHEMBL24836229 | 0.77 | FAAH (0.76) | CASP3FAAHMGLLG6PD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-11541044-B2 | K-Ras modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| US-11358940-B2 | K-Ras modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-14 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-11208388-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2021-12-28 | — | — | US | disclosed |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| EP-0018100-B1 | SUBSTITUTED AROMATIC BIOLOGICALLY ACTIVE COMPOUND, A PROCESS FOR ITS PREPARATION AND ITS USE AS BIOCIDE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-01-18 | — | — | EP | disclosed |
| EP-0018100-A2 | Substituted aromatic biologically active compound, a process for its preparation and its use as biocide | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | CASP3 478/4885FAAH 1433/4885MGLL 616/4885 |
| US-11541044-B2 | K-Ras modulators | KRAS, HRAS, NRAS | CASP3 2779/4885FAAH 3107/4885MGLL 3410/4885 |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CASP3 919/4885FAAH 3508/4885MGLL 2601/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | CASP3 1825/4885FAAH 3687/4885MGLL 2774/4885 |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | CASP3 409/4885FAAH 957/4885MGLL 2503/4885 |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CASP3 478/4885FAAH 1433/4885MGLL 616/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | CASP3 919/4885FAAH 3508/4885MGLL 2601/4885 |
| US-11208388-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | CASP3 1080/4885FAAH 2501/4885MGLL 1913/4885 |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CASP3 891/4885FAAH 706/4885MGLL 192/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | CASP3 2516/4885FAAH 3685/4885MGLL 3812/4885 |
| US-11358940-B2 | K-Ras modulators | KRAS, HRAS, NRAS | CASP3 2988/4885FAAH 4099/4885MGLL 3593/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CASP3 478/4885FAAH 1433/4885MGLL 616/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CASP3 478/4885FAAH 1433/4885MGLL 616/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CASP3 919/4885FAAH 3508/4885MGLL 2601/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CASP3 891/4885FAAH 706/4885MGLL 192/4885 |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CASP3 891/4885FAAH 706/4885MGLL 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.